| Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B. 1.617. 2) variant surge in India: a test-negative, case-control study and a … R Thiruvengadam, A Awasthi, G Medigeshi, S Bhattacharya, S Mani, ... The Lancet Infectious Diseases 22 (4), 473-482, 2022 | 74 | 2022 |
| Awakening the “guardian of genome”: reactivation of mutant p53 A Binayke, S Mishra, P Suman, S Das, H Chander Cancer chemotherapy and pharmacology 83, 1-15, 2019 | 44 | 2019 |
| Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection ZA Rizvi, R Dalal, S Sadhu, A Binayke, J Dandotiya, Y Kumar, ... Elife 11, e73522, 2022 | 37 | 2022 |
| Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 … S Thuluva, V Paradkar, SR Gunneri, V Yerroju, RR Mogulla, PV Suneetha, ... Vaccine 40 (49), 7130-7140, 2022 | 17 | 2022 |
| SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines R Thiruvengadam, A Binayke, A Awasthi The Lancet Infectious Diseases 22 (3), 301-302, 2022 | 17 | 2022 |
| Analysis of diversity of actinomycetes from arid and saline soils at Rajasthan, India A Binayke, S Ghorbel, N Hmidet, A Raut, A Gunjal, A Uzgare, N Patil, ... Environmental Sustainability 1 (1), 61-70, 2018 | 14 | 2018 |
| Cellular immune responses are preserved and may contribute to Chadox1 ChAdOx1 nCoV-19 vaccine effectiveness against infection due to SARS-CoV-2 B· 1· 617· 2 delta variant … R Thiruvengadam, A Awasthi, G Medigeshi, S Bhattacharya, S Mani, ... | 13 | 2021 |
| Immunogenic superiority and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™(ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter … S Thuluva, V Paradkar, K Turaga, SR Gunneri, V Yerroju, R Mogulla, ... Medrxiv, 2022.03. 20.22271891, 2022 | 9 | 2022 |
| Proinflammatory innate cytokines and distinct metabolomic signatures shape the T cell response in active COVID-19 A Binayke, A Zaheer, J Dandotiya, SK Gupta, S Mani, MR Tripathy, ... Vaccines 10 (10), 1762, 2022 | 4 | 2022 |
| IL-9 aggravates SARS-CoV-2 infection and exacerbates associated airway inflammation S Sadhu, R Dalal, J Dandotiya, A Binayke, V Singh, MR Tripathy, V Das, ... Nature Communications 14 (1), 4060, 2023 | 1 | 2023 |
| SARS-CoV-2 and its variants, but not Omicron, induces thymic atrophy and impaired T cell development ZA Rizvi, S Sadhu, J Dandotiya, A Binyka, P Sharma, V Singh, V Das, ... bioRxiv, 2022.04. 07.487556, 2022 | 1 | 2022 |
| Innate immune response and distinct metabolomic signatures together drive and shape the SARS-CoV-2-specific T cell response during COVID-19 A Binayke, A Zaheer, J Dandotiya, SK Gupta, S Mani, M Tripathi, U Madan, ... bioRxiv. 2022, 2022 | 1 | 2022 |
| Cell Mediated Immunity (CMI) for SARS-CoV-2 Infection Among General Population of North India: A Cross-Sectional Analysis from a Sub-Sample of a Large Sero-Epidemiological Study P Misra, P Garg, A Awasthi, S Kant, SK Rai, M Ahmad, R Guleria, TJ Deori, ... | | 2023 |
| Case report: Correlation of immune profiling and exceptional response to immune checkpoint inhibitor in a patient with head and neck cancer K Jain, DK Rathore, S Ganguly, A Binayke, NK Ganguly, A Awasthi, ... Journal of Cancer Research and Therapeutics, 2023 | | 2023 |
| Artemotil mediates protection in experimental colitis through the induction of Type 1 regulatory T cells U Madan, B Verma, A Binayke, A Awasthi The Journal of Immunology 210 (1_Supplement), 238.05-238.05, 2023 | | 2023 |
| Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™(ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized … S Thuluva, V Paradkar, SR Gunneri, V Yerroju, R Mogulla, PV Suneetha, ... Human Vaccines & Immunotherapeutics, 2203632, 2023 | | 2023 |
| Antiviral activity of the human endogenous retrovirus‐R envelope protein against SARS‐CoV‐2 S Ansari, N Gupta, R Verma, ON Singh, J Gupta, A Kumar, MK Yadav, ... EMBO reports, e55900, 2023 | | 2023 |
| Immunogenicity and safety of Biological Es CORBEVAX vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD or … S Thuluva, V Paradkar, S Gunneri, V Yerroju, RR Mogulla, ... medRxiv, 2022.12. 29.22284049, 2023 | | 2023 |
| Human endogenous retrovirus-R envelope is a host restriction factor against severe acute respiratory syndrome-coronavirus-2 N Gupta, S Ansari, R Verma, ON Singh, MK Yadav, A Binayke, K Jakhar, ... bioRxiv, 2022.08. 05.502940, 2022 | | 2022 |
Amit AwasthiTranslational Health Science and Technology Institute在 thsti.res.in 的电子邮件经过验证
